Document Detail

Prognosis of patients treated for intracranial metastases with whole-brain irradiation.
MedLine Citation:
PMID:  9677016     Owner:  NLM     Status:  MEDLINE    
Seventy-five patients with brain metastases from solid tumours were treated with whole-brain irradiation at our institution between 1990 and 1993. The primary cancers included 35 cases of lung cancer, 19 cases of breast cancer, nine cases of renal-cell cancer, six cases of melanoma and six cases of other primary sites. In each case the total dose to the whole brain was at least 25 gray (Gy). The primary site, age, performance status, number of brain metastases and the presence of extracranial disease were studied as prognostic factors for survival. The median survival for the whole population was 4 months (range 1-62 months). The patients with the brain as the only metastatic site had significantly better survival (P = 0.019) than those with both intracranial and extracranial metastatic sites. Poor performance status at the time of diagnosis of brain metastases was also related to short survival (P = 0.001). None of the other studied variables had prognostic significance. Four of the 75 patients with primary tumour sites in the breast (two patients) and the kidney (two patients) survived for more than 2 years. In general, patients with breast cancer had better survival than patients with other primary cancers. Our study confirms the generally poor prognosis of cancer with brain metastases, although individual patients may survive several years after whole-brain irradiation. Approximately two-thirds of the patients experienced a relief in symptoms allowing a reduction in the dose of corticosteroid medication, which clearly supports the use of whole-brain radiotherapy as a palliative treatment.
J T Sundström; H Minn; K K Lertola; E Nordman
Related Documents :
8499146 - Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity again...
25046616 - Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5...
20090516 - Muc16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeni...
19577856 - Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastase...
21750136 - Biplane fluoroscopy-guided radiofrequency ablation combined with chemoembolisation for ...
15629596 - Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for li...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of medicine     Volume:  30     ISSN:  0785-3890     ISO Abbreviation:  Ann. Med.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-09-25     Completed Date:  1998-09-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8906388     Medline TA:  Ann Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  296-9     Citation Subset:  IM    
Department of Oncology and Radiotherapy, Turku, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Brain Neoplasms / mortality,  radiotherapy*,  secondary*
Breast Neoplasms / pathology
Cobalt Radioisotopes / therapeutic use*
Cranial Irradiation*
Kidney Neoplasms / pathology
Lung Neoplasms / pathology
Middle Aged
Radioisotope Teletherapy*
Radiotherapy, High-Energy
Retrospective Studies
Skin Neoplasms / pathology
Survival Rate
Reg. No./Substance:
0/Cobalt Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Polymerase chain reaction in the detection of microbes in amniotic fluid.
Next Document:  Association between elevated plasma total homocysteine and increased common carotid artery wall thic...